Latest News

Melbourne-based privately owned Australian biotechnology Technovalia has partnered with the Vax4COVID Alliance and BioNet to start a phase one trial of the COVIGEN COVID-19 gene-based vaccine.

Osprey Medical (ASX:OSP) has announced an agreement under which Australian-owned medical distribution company Regional Health Care Group (RHCG) will exclusively distribute its products across Australia and New Zealand.

To inform the ongoing implementation of a tele-trial model, feedback is sought from sponsors that have experience in implementing tele-trials in Australia or are actively considering utilising tele-trials.

“Chimeric is excited to join City of Hope in its quest to find more effective cancer therapies. This is an exceedingly rare opportunity to acquire a promising technology in one of the most exciting areas of immuno-oncology today,” said Chimeric’s executive chairman Paul Hopper.

Australian company Atomo Diagnostics (ASX:AT1) has announced it has entered an agreement with Indian specialist diagnostic company DIVOC Laboratories to launch its TGA Approved and CE Marked AtomoRapid COVID-19 antibody test in the Indian market.

Telix Pharmaceuticals (ASX:TLX) has submitted a New Drug Application to the US FDA for its radiopharmaceutical targeting Prostate-Specific Membrane Antigen for the imaging of prostate cancer using Positron Emission Tomography.

A startup company developing treatments for inflammatory diseases based on a research partnership between The University of Queensland and Trinity College Dublin has been acquired in a landmark deal.

AusBiotech calls on its Members for feedback on its response to a new parliamentary inquiry that is considering the “approval processes for new drugs and novel medical technologies in Australia”.

The federal government has announced funding from the MRFF for three more Australian COVID-19 vaccine candidates, including one based on mRNA technology and another administered using a needle-free system.

Melbourne-based company Neuren Pharmaceuticals (ASX:NEU) says it has initiated the manufacture of NNZ-2591 to supply the planned phase two clinical trials.

Kazia said the collaboration will investigate the use of its investigational new drug, paxalisib (formerly GDC-0084), in primary central nervous system lymphoma.

Regenerative medicine company Orthocell (ASX:OCC) has announced the publication of positive pre-clinical and clinical results for the use of its CelGro in enhancing repair of critical bone defects in the 'Tissue Engineering' Journal.